Aco
-
Upload
julian-duran -
Category
Health & Medicine
-
view
60 -
download
0
Transcript of Aco
![Page 1: Aco](https://reader035.fdocuments.mx/reader035/viewer/2022070520/58f9b155760da3da068bbfc2/html5/thumbnails/1.jpg)
NUEVOS ANTICOAGULANTES
ORALES
Dr. Julián Andrés DuránResidente 1° año Cardiología
Instituto Cardiovascular Denton Cooley
![Page 2: Aco](https://reader035.fdocuments.mx/reader035/viewer/2022070520/58f9b155760da3da068bbfc2/html5/thumbnails/2.jpg)
EL ANTICOAGULANTE IDEAL
• ORAL• UNA DOSIS DIARIA• RAPIDEZ ACCIÓN• MONITORIZACIÓN LIMITADA,
AUNQUE DISPONIBLE• NO INTERACCIONES• ANTÍDOTO• ECONÓMICO
2
![Page 3: Aco](https://reader035.fdocuments.mx/reader035/viewer/2022070520/58f9b155760da3da068bbfc2/html5/thumbnails/3.jpg)
![Page 4: Aco](https://reader035.fdocuments.mx/reader035/viewer/2022070520/58f9b155760da3da068bbfc2/html5/thumbnails/4.jpg)
MECANISMO DE ACCIÓN – FACTORES DE COAGULACION
Direct Thrombin Inhibitors
DabigatranAZD-0837Fibrinogeno Fibrina
IIa
II
Xa
Factor Xa Inhibitors
RivaroxabanApixabanEdoxabanBetrixabanEribaxaban
Idraparinux (SQ)LY517717
YM150TAK-442
VIIa
X IX
IXaVIIIa
Warfarin Sites of Action
IIVIIIXX
![Page 5: Aco](https://reader035.fdocuments.mx/reader035/viewer/2022070520/58f9b155760da3da068bbfc2/html5/thumbnails/5.jpg)
5
DABIGATRAN ETEXILATE RIVAROXABAN APIXABAN
Marca Pradaxa® Xarelto® Eliquis®
Diana IIa Xa Xa
Administración Dos veces diarias Una vez al día Dos veces al día
Pico plasmático 2-4 horas 2.5-4 horas 3-4 horas
Dosis 110 o 150 mg BID 20 mg (15 mg si IR) 5 mg BID
Biodisponibilidad (%) ~7% ~90% ~66%
Unión a prots ~35% Muy elevada
T1/2 (hrs) 12-14 9-13 8-15
Excreción renal 90-95% (no si ClCr<30) 70% (no si ClCr<30) 30%
Interacciones farmacológicas
PPI decrease absorptionP-glycoprotein substrate
Potent 3A4 inhibitorsP-glycoprotein inhibitors
Potent 3A4 inhibitors
Monitorización No No No
Antídoto No No No
![Page 6: Aco](https://reader035.fdocuments.mx/reader035/viewer/2022070520/58f9b155760da3da068bbfc2/html5/thumbnails/6.jpg)
![Page 7: Aco](https://reader035.fdocuments.mx/reader035/viewer/2022070520/58f9b155760da3da068bbfc2/html5/thumbnails/7.jpg)
![Page 8: Aco](https://reader035.fdocuments.mx/reader035/viewer/2022070520/58f9b155760da3da068bbfc2/html5/thumbnails/8.jpg)
![Page 9: Aco](https://reader035.fdocuments.mx/reader035/viewer/2022070520/58f9b155760da3da068bbfc2/html5/thumbnails/9.jpg)
NUEVOS ANTICOAGULANTES ORALES 9
![Page 10: Aco](https://reader035.fdocuments.mx/reader035/viewer/2022070520/58f9b155760da3da068bbfc2/html5/thumbnails/10.jpg)
NACO: ICTUS ISQUÉMICO
NUEVOS ANTICOAGULANTES ORALES 10
![Page 11: Aco](https://reader035.fdocuments.mx/reader035/viewer/2022070520/58f9b155760da3da068bbfc2/html5/thumbnails/11.jpg)
NOCA: ICTUS HEMORRÁGICO
NUEVOS ANTICOAGULANTES ORALES 11
![Page 12: Aco](https://reader035.fdocuments.mx/reader035/viewer/2022070520/58f9b155760da3da068bbfc2/html5/thumbnails/12.jpg)
NACO: SANGRADOS MAYORES
NUEVOS ANTICOAGULANTES ORALES 12
![Page 13: Aco](https://reader035.fdocuments.mx/reader035/viewer/2022070520/58f9b155760da3da068bbfc2/html5/thumbnails/13.jpg)
NACO: COMPARACIÓN GLOBAL
13
![Page 14: Aco](https://reader035.fdocuments.mx/reader035/viewer/2022070520/58f9b155760da3da068bbfc2/html5/thumbnails/14.jpg)
G
![Page 15: Aco](https://reader035.fdocuments.mx/reader035/viewer/2022070520/58f9b155760da3da068bbfc2/html5/thumbnails/15.jpg)
www.sparctool.com
![Page 16: Aco](https://reader035.fdocuments.mx/reader035/viewer/2022070520/58f9b155760da3da068bbfc2/html5/thumbnails/16.jpg)
![Page 17: Aco](https://reader035.fdocuments.mx/reader035/viewer/2022070520/58f9b155760da3da068bbfc2/html5/thumbnails/17.jpg)
![Page 18: Aco](https://reader035.fdocuments.mx/reader035/viewer/2022070520/58f9b155760da3da068bbfc2/html5/thumbnails/18.jpg)
LIMITACIONES DE LOS NACO
• NO MONITORIZABLES• VIDA MEDIA CORTA• NO ANTÍDOTO• PROBABLEMENTE REQUIEREN AJUSTE DE
DOSIS EN INSUFICIENCIA RENAL O HEPÁTICA
• COSTO
18
![Page 19: Aco](https://reader035.fdocuments.mx/reader035/viewer/2022070520/58f9b155760da3da068bbfc2/html5/thumbnails/19.jpg)
LIMITACIONES DE LOS NACO
NUEVOS ANTICOAGULANTES ORALES 19
![Page 20: Aco](https://reader035.fdocuments.mx/reader035/viewer/2022070520/58f9b155760da3da068bbfc2/html5/thumbnails/20.jpg)
GRACIAS !!
!